Abstract
Leukemic cell and plasma concentrations of daunorubicin were examined serially in a patient with acute lymphoblastic leukemia following administration of the drug by two different regimens: A an iv bolus dose of 50 mg/m 2, and regimen B a loading dose of 15 mg/m 2 followed by 35 mg/m 2 infused over 4 hours. Peak plasma levels were four times higher after regimen A than B, whereas leukemic cell concentrations were not significantly different. No difference in acute toxicity or therapeutic efficacy was seen after either method of administration. However, we have demonstrated that peak plasma levels of daunorubicin can be reduced by continuous infusion without significantly altering target tissue concentrations.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2085-2088 |
| Number of pages | 4 |
| Journal | Cancer Treatment Reports |
| Volume | 66 |
| Issue number | 12 |
| State | Published - 1982 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Cellular and plasma kinetics of daunorubicin by two methods of administration in a patient with acute leukemia. / DeGregorio, M. W.; Carrera, C. J.; Klock, J. C.; Pegelow, C. H.; Wilbur, J. R.
In: Cancer Treatment Reports, Vol. 66, No. 12, 1982, p. 2085-2088.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cellular and plasma kinetics of daunorubicin by two methods of administration in a patient with acute leukemia
AU - DeGregorio, M. W.
AU - Carrera, C. J.
AU - Klock, J. C.
AU - Pegelow, C. H.
AU - Wilbur, J. R.
PY - 1982
Y1 - 1982
N2 - Leukemic cell and plasma concentrations of daunorubicin were examined serially in a patient with acute lymphoblastic leukemia following administration of the drug by two different regimens: A an iv bolus dose of 50 mg/m 2, and regimen B a loading dose of 15 mg/m 2 followed by 35 mg/m 2 infused over 4 hours. Peak plasma levels were four times higher after regimen A than B, whereas leukemic cell concentrations were not significantly different. No difference in acute toxicity or therapeutic efficacy was seen after either method of administration. However, we have demonstrated that peak plasma levels of daunorubicin can be reduced by continuous infusion without significantly altering target tissue concentrations.
AB - Leukemic cell and plasma concentrations of daunorubicin were examined serially in a patient with acute lymphoblastic leukemia following administration of the drug by two different regimens: A an iv bolus dose of 50 mg/m 2, and regimen B a loading dose of 15 mg/m 2 followed by 35 mg/m 2 infused over 4 hours. Peak plasma levels were four times higher after regimen A than B, whereas leukemic cell concentrations were not significantly different. No difference in acute toxicity or therapeutic efficacy was seen after either method of administration. However, we have demonstrated that peak plasma levels of daunorubicin can be reduced by continuous infusion without significantly altering target tissue concentrations.
UR - http://www.scopus.com/inward/record.url?scp=0020366688&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020366688&partnerID=8YFLogxK
M3 - Article
C2 - 6958366
AN - SCOPUS:0020366688
VL - 66
SP - 2085
EP - 2088
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
SN - 0027-8874
IS - 12
ER -